Grand prize winner, Traci Johannson, 3 Sons Foods; Jody Hall, H-E-B; George Johannson; Winell Herron, H-E-B; Luke and Ayden Johannson; James Harris, H-E-B. Photo courtesy of H-E-B

Five homegrown Texas businesses are enjoying Lone Star State-sized bragging rights after a big win on August 8. The entrepreneurs are the collective winners of H-E-B's sixth-annual Primo Picks Quest for Texas Best contest, which recognizes the most innovative products. Collectively, the winners earn $80,000 in prizes, and, just as important, coveted shelf space in H-E-Bs across the state.

A Houston family leads the way, joining winners from Austin; San Antonio; Woodway; and Atlanta, Texas. Houston's 3 Sons Foods won a grand prize of $25,000 and featured placement as a Texas Primo Pick for Diablo Verde Sauce, a creamy cilantro offering. The company is owned by and operated by Traci Johannson and her three young sons: George (11), Luke (14), and Ayden (16). A portion of Diablo Verde sales goes to the International Rhino Foundation to help stop the illegal poaching of rhinos, according to a release.

First place honors — and a $20,000 prize — go to Austin's Courtney Ray Goodson for her Uncle Ray's Peanut Brittle. Inspired by her great uncle Ray's 35-year-old recipe, Goodson's offerings include Bacon Pecan, Butternut, Pecan, and classic Peanut Brittle.

Hailing from Woodway, Texas, Derek Newball landed second place and $15,000 for his EVOKE collagen drink. Capitalizing on the collagen drink trend, Newball's coconut-based products are meant to benefit skin, hair, joints, and bones, and come in coconut, mandarin coconut, and pineapple coconut flavors.

To the Moon Family Foods, based in Atlanta, Texas, tied for third place (a $10,000 prize) with its To the Moon Family Foods Nutty-Carrot Spread. Creators Kay Lynn York and Joan Reece combine carrots, pecans, and "mouthwatering" spices for a spread to be used on sandwiches; meats; or even rolled in balls, coated, and fried.

Tying with To the Moon at third place (and a $10,000 prize) is San Antonio's Grain4Grain Low-Carb Flour and Mix. Owners Yoni Medhin and Matt Mechtly recycle spent grains from local microbreweries to make a low-carb, high-protein, high-fiber flour. For every pound of flour sold, Grain4Grain donates a pound to those in need.

The 2019 Quest for Texas Best competition drew more than 800 entries from nearly 140 cities and towns across the state after a call for entries in February of this year. Through two qualifying rounds, submissions were judged on taste and flavor, customer appeal, value, uniqueness, market potential, and differentiation from current products at most H-E-B stores.

"Each of these 20 competitors displayed unprecedented creativity, style, and commitment to providing outstanding, unique products for our consideration," said James Harris, director of diversity & inclusion and supplier diversity at H-E-B, in a statement. "In fact, the entries were so good that we ended up with five winners this year. We are delighted to share that diversity and ingenuity with our customers across the state."

------

This story originally appeared on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”

Houston startup raises $6M to scale home-based healthcare platform

fresh funding

As healthcare systems race to expand care beyond hospitals and into the home, investors are placing bigger bets on the infrastructure needed to make that shift possible.

This month, Rosarium Health announced it has raised $6 million in seed funding led by Kalos Ventures, with participation from ResilienceVC, Rock Health Capital, Symphonic Capital, Black Tech Nations Ventures and others.

The investment will help the Houston-based startup continue to build its platform, which features a national network of 800-plus clinicians and 3,000-plus contractors to coordinate home accessibility upgrades and modifications for seniors and people living with disabilities.

For founder and CEO Cameron Carter, the company’s mission grew out of firsthand caregiving experiences.

“From my own personal caregiving experiences, I realized that the benefits exist on paper, but not in reality,” Carter said in a news release. “Families are being left to figure out the paperwork and installations all on their own, which shouldn’t be how this works.”

While Medicare Advantage and Medicaid plans have expanded coverage for home-based services and accessibility modifications, the logistics behind delivering those services often remain fragmented.

Rosarium’s platform coordinates the entire process, from clinical assessments and referrals to contractor management, documentation, reimbursement and installation.

“A clinician can document that a home isn’t safe and a plan can approve a benefit, but there’s no one that’s responsible for making sure the work actually gets done,” Carter says. “We built the missing piece.”

The company was founded in 2021 as Rose Health and was a 2023 participant in the Texas Medical Center’s Accelerator for HealthTech program. It has scaled quickly, building a network of more than 800 clinicians and 3,000 contractors across 34 states.

Rosarium is currently in-network for 1.2 million Medicare and Medicaid lives, with projected coverage expected to reach nearly 4 million by the end of the year, according to the release.

“We’re excited to back Cameron because he and the team at Rosarium are building the infrastructure healthcare needs right now to make the home a safe and comfortable place of care,” Kate Ballinger, investor at Kalos Ventures, added in the release.

As part of the recent investment, Ballinger will join Rosarium’s board of directors.

With eyes on the future, Rosarium plans to grow its partnerships with Medicaid and Medicare Advantage plans, including CalViva and Community Health Plan of Imperial Valley, strengthening its presence in California while expanding access to underserved communities.

Additionally, Carter predicts that home-based healthcare will be part of a broader transformation happening across the industry.

“There’s a growing recognition that health outcomes are shaped by what happens in the home,” he said in the release. “The future of healthcare isn’t just treating people after something goes wrong. It’s creating environments that help prevent those problems in the first place.”